Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a blank check company formed to complete a merger, share exchange, asset acquisition, or similar business combination with one or more operating businesses. It is organized as a special purpose acquisition company (SPAC) and is based in the United States, with its capital structure designed to fund an eventual acquisition.

0.07

0.07

— Translational Development Acquisition Corp.
%
SPAC formation and capital raising0% Units sold in the IPO and related private placement securities used to fund a future transaction.
Trust account management0% Cash and marketable securities held in trust pending completion of a business combination.
Business combination execution0% Identification, due diligence, negotiation, and closing of an acquisition or merger target.
Sponsor and administrative support0% Ongoing sponsor-backed administrative services and transaction support during the search period.

The company does not sell products or services to traditional end customers; its counterparties are public-market...

  • Public SPAC investorsprimary

    Buy units and shares for exposure to a future acquisition transaction and redemption rights.

  • Sponsor and affiliatesprimary

    Provide working capital loans, administrative support, and transaction sponsorship.

  • Potential merger targetsprimary

    Enter into a business combination to become a public operating company through the SPAC.

  • Underwriters and placement counterpartiessecondary

    Provide offering execution and receive deferred fees or private placement securities.

The company is incorporated in the Cayman Islands and operates as a U.S.-listed SPAC with its transaction search and...

  • •Incorporated in the Cayman Islands
  • •U.S.-listed capital markets vehicle
  • •Transaction search and advisory activity centered in the United States
  • •No operating revenue geography disclosed
  • •Geography matters mainly for legal and listing structure

The company’s strategy is to identify, diligence, and complete an initial business combination before its deadline...

01
Complete an initial business combinationshort-term

The SPAC exists to close a qualifying transaction and avoid liquidation.

02
Preserve liquidity for search and diligenceshort-term

The company needs cash to fund target evaluation, legal work, and transaction costs.

03
Structure financing for closingmedium-term

A transaction may require additional equity or debt if redemptions are high.

The main risk is failure to complete a business combination before the deadline, which would trigger liquidation and...

critical

Mandatory liquidation if no business combination is completed on time

The company has a fixed completion window and must dissolve if it misses the deadline.

Scope
All shareholders and the SPAC structure
Materiality
high
high

Insufficient liquidity for transaction costs and due diligence

Cash outside the trust account is limited and search-stage expenses can exceed estimates.

Scope
Operating runway and deal execution
Materiality
high
high

High redemption levels at closing

Public shareholders may redeem shares, reducing cash available to fund the acquisition.

Scope
Business combination financing
Materiality
high
medium

Dependence on sponsor financing and support

Working capital loans and administrative support are important to maintain operations.

Scope
Search period liquidity
Materiality
medium
Trust account fair value and interest income
Reported net income and balance sheet cash-equivalent presentation
Going-concern assessment
Disclosure of substantial doubt and liquidation assumptions
Deferred underwriting fee
Future transaction costs and closing economics
Redemption and liquidation accounting
Equity classification and available transaction funding

Technology & Telecommunication Acquisition Corp

TETEF · Services-Business Services, NEC

Transcode Therapeutics, Inc.

RNAZ · Pharmaceutical Preparations

D. Boral ARC Acquisition I Corp.

BCAR · Services-Prepackaged Software

Trailblazer Acquisition Corp.

BLZR · Blank Checks

Titan Acquisition Corp.

TACH · Blank Checks

4D Molecular Therapeutics, Inc.

FDMT · Biological Products, (No Diagnostic Substances)

: 29.4.2026